A DNA test to detect esophageal precancer.

Empowering clinicians through early detection to prevent esophageal cancer before it develops.

learn about lucid
  • NEWS STORY
New technology helps screen SC firefighters for pre-cancer
Read article
  • NEWS STORY
New test can help with early screening for esophageal cancer
Read article
  • NEWS STORY
Chesapeake firefighters attack an increased cancer risk with early detection screening
Read article

precancer detection

Early detection powered by targeted Next Generation Sequencing

The groundbreaking EsoGuard DNA test is changing the way esophageal precancer is detected. Now disease can be identified in a simple office-based visit without endoscopy.

Learn About ESOGUARD

Patient Stories

Don M.
Patient

"If you're seeing symptoms of reflux, a chronic cough, ask your doctor to screen you. Don't take reflux lightly. Reflux can equal Barrett's, can equal esophageal cancer."

Scott S.
Patient

"I caught my Barrett's esophagus early enough in the stages that I avoided surgery and they could cure my problem without doing a major surgery. I felt that the EsoGuard test saved my life."

Angela W.
Patient

"I was unaware that I had GERD because my symptoms (cough, difficulty swallowing, and hoarseness) were "normal" to me. After receiving the results I was referred to a GI specialist for an upper GI scope and diagnosed with Barrett's esophagus. I was not symptomatic so I am grateful that this test screened for the precancerous condition. Knowledge is power!  I gained valuable information about my health and made lifestyle changes. I will repeat the scope in 2 years to determine if my condition has stabilized or worsened."

Daniel R.
Patient

“It was two minutes for the rest of my life, because of the EsoGuard test my disease was caught and treated.”

Brian L.
Patient

"I got screened as a baseline check, to see if there are any indicators of a precancer, a cancer...really to be proactive for my own health. Early detection is everything"

Clinician testimonials

Srinadh Komanduri, MD, MS FAGA, FASGE
Associate Chief, Division of Gastroenterology and Hepatology
Northwestern University

"Providing EsoGuard to my patients is paramount because it empowers early detection of Barrett’s esophagus, non-invasively. By offering this test, we can catch potential issues at their earliest stages, allowing for timely intervention and improved patient outcomes."

Philip Woodworth, MD, FACS
Surgeon
Institute of Esophageal and Reflux Surgery
Director of Heartburn and Reflux Surgery Sky Ridge Medical Center

“EsoGuard is providing something that hasn’t been available before, it allows at-risk patients to be evaluated earlier. Since it’s available in-office patients can easily be tested, and if-needed, treated before cancer develops.”

Scott Corbett, MD, FASGE
Gastroenterologist
Director of the Barrett's Esophagus Institute
Florida Digestive Health Specialists

"Most patients at risk for esophageal adenocarcinoma never or rarely get symptoms, this technology gives us an opportunity to find many of the 94-95 percent of patients who are at risk for developing esophageal cancer but don’t know it. People don’t need to die from this disease"

Seper Dezfoli, MD
GASTROENTEROLOGIST
Prestige GI

“Offering the EsoGuard test is a crucial part of my practice because it allows us to detect Barrett’s esophagus at an early, treatable stage. This non-invasive test is quick for patients and allows us to easily screen for precancer, ultimately improving outcomes and saving lives.”

Host a #CheckYourFoodTube Esophageal Precancer Testing Event

Firefighters have a 62% increased risk of developing esophageal cancer and 39% increased risk of dying of the disease.1 The EsoGuard DNA test offers early detection for those at increased risk, which is why we partner with fire departments across the country to host convenient group screening events.

Request an event

Careers

Join the team revolutionizing early detection

At Lucid Diagnostics, we believe early detection will make esophageal cancer a disease of the past. We're using next generation sequencing to fundamentally change the way esophageal precancer is detected. Join a diverse and inclusive team where collaboration and mutual respect are the foundation of our success. 

View Positions

Press releases

Read the latest news from Lucid Diagnostics
December 3, 2024

Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones

Read article
November 20, 2024

Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test

Read article
November 18, 2024

Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

Read article
November 13, 2024

Lucid Diagnostics Provides Business Update and Third Quarter 2024 Financial Results

Read article

Contact us

Get in touch with our team
contact us
References:
1. IAFF date 1.1.2002 to 3.31.2017—NIOSH Research